Fortrea Reports Second Quarter 2024 Results

For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 million GAAP net loss of$(99.3) million Adjusted EBITDA of $55.2 million GAAP and adjusted diluted loss per share of$(1.11) and $(0.03), respectively Book-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 months Completed divestiture of assets relating to the Endpoint Clinical and Patient Access businesses Debt paydown of$504 million in the quarter using initial divestiture and securitizatio ...